Add BrightSurf on Google Email

Leading AI models struggle to identify genetic conditions from patient-written descriptions

Researchers found large language models are more accurate with concise, textbook-like medical questions than patient-written summaries. The models achieved higher accuracy when using standardized language, but struggled with variable phrasing and format of patient write-ups.

SourceNIH/National Human Genome Research Institute·JournalAmerican Journal of Human Genetics·TypeExperimental study·DateAug 14, 2024

Is free genetic testing really free?

A recent commentary in the Canadian Medical Association Journal argues that free genetic testing may have trade-offs, particularly regarding patient data protection and potential harm. The authors emphasize the need for comprehensive guidance to help practitioners navigate this complex issue.

SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·TypeCommentary/editorial·DateJul 29, 2024

Many breast cancer survivors do not receive genetic testing, despite being eligible

A new study from the University of Michigan Health Rogel Cancer Center found that nearly three-quarters of patients who were eligible for genetic testing at diagnosis received it over the study period. Those who got testing and found they had a genetic variant were most likely to talk with their family about the results.

SourceMichigan Medicine - University of Michigan·JournalJournal of Clinical Oncology·TypeSurvey·DateJul 16, 2024

An innovative test to diagnose chagas disease in newborns

A novel diagnostic test combining LAMP molecular amplification with a 3D printer-based DNA extraction system shows comparable sensitivity to PCR, offering a simple and rapid solution for detecting T. cruzi infection in newborns. Early detection is crucial for effective treatment, which was successfully applied in the study.

SourceBarcelona Institute for Global Health (ISGlobal)·JournalThe Lancet Microbe·TypeExperimental study·DateJul 3, 2024

Novel blood test helps improve cancer treatments

A new liquid biopsy method analyzes gene fragments in the bloodstream to detect and track cancer, enabling oncologists to tailor treatment approaches to individual patients. This non-invasive test can help monitor treatment success, detect cancer recurrence, and improve patient quality of life.

SourceUniversity of Zurich·JournalRadiotherapy and Oncology·TypeExperimental study·DateJul 1, 2024

Rapid test of cerebrospinal fluid decreases time to diagnosis for brain tumors

Researchers developed a rapid genotyping test for patients with central nervous system lesions, detecting key mutations associated with brain cancers in samples taken during a lumbar puncture. The test eliminated the need for surgical brain biopsies in seven cases and significantly accelerated time to treatment, from an average of 12 d...

SourceMass General Brigham·JournalBlood·TypeExperimental study·DateJun 17, 2024

Significant reduction in alcohol consumption among young excessive drinkers: personalized alcohol-reduction advice based on genetic information

A study published in BMC Medicine found that personalized alcohol-reduction advice based on genetic information significantly reduced alcohol consumption among young excessive drinkers. The intervention group showed lower alcohol consumption and AUDIT-C scores compared to the control group, with continued reductions in scores over time.

SourceUniversity of Tsukuba·JournalBMC Medicine·DateJun 17, 2024

Low doses of kretek cigarette smoke altered rat lung histometric, and overexpression of the p53 gene

A study found that low doses of filtered kretek cigarette smoke altered rat lung histometric measurements, increasing the size of respiratory bronchioles. P53 gene overexpression was also observed in response to exposure. The findings suggest potential health risks from even low levels of kretek cigarette smoke.

SourceBentham Science Publishers·JournalThe Open Respiratory Medicine Journal·DateJun 6, 2024

Lowering fecal immunochemical test positivity threshold vs multitarget stool RNA testing for colorectal cancer screening

This study found that lowering the fecal immunochemical test positivity threshold can achieve comparable sensitivity and specificity to the multitarget stool RNA test without additional testing. The findings are similar to previous observations with multitarget stool DNA testing, suggesting a potentially simpler screening method.

SourceJAMA Network·JournalJAMA·DateJun 1, 2024

Genes driving age-related blood cell mutations uncovered

Scientists have discovered 17 new genes involved in clonal haematopoiesis, a process associated with ageing linked to increased risks of blood cancers. The findings highlight the clinical significance of these genes in driving mutant blood cell clones, offering new avenues for studying disease development and promoting healthier ageing.

SourceWellcome Trust Sanger Institute·JournalNature Genetics·TypeObservational study·DateMay 14, 2024

Testing for residual cancer cells before blood cell transplant therapy is important and practical, new study finds

A new study published in JAMA Oncology highlights the importance of testing for measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) undergoing bone marrow transplants. The researchers found that detecting MRD can help predict cancer recurrence and improve patient outcomes.

SourceVirginia Tech·JournalJAMA Oncology·TypeData/statistical analysis·DateMay 2, 2024

Access to genomic medicine illustrates precision medicine’s delicate future

A new study found that access to genomic testing for cancer is limited by factors such as test availability, patient information, and insurance coverage in both Japan and Switzerland. Despite universal insurance coverage, barriers persist due to differences in hospital accessibility, language barriers, and varying levels of reimbursement.

SourceOsaka University·JournalFrontiers in Genetics·TypeCase study·DateApr 8, 2024

Testing method could point thousands more cancer patients to lifesaving treatment

Researchers found that next-generation sequencing (NGS) identified more patients with microsatellite instability than immunohistochemistry (IHC), potentially leading to thousands of missed diagnoses and patients receiving incorrect treatment. NGS could guide the standard of care towards using this test method instead of IHC.

SourceUniversity of Oklahoma·JournalCancer Cell·TypeData/statistical analysis·DateMar 21, 2024

Understanding genetic risk could save sight and predict multiple sclerosis earlier in young people

Researchers have developed a genetic risk tool that combines genetic factors with demographic information to improve MS risk prediction in young people presenting with optic neuritis. The study shows that this approach can help identify patients at high risk of MS, potentially enabling earlier treatment and improving long-term health.

SourceUniversity of Exeter·JournalNature Communications·TypeObservational study·DateFeb 28, 2024

New assay identifies clinically relevant gene fusions in pediatric tumors more accurately and efficiently

Researchers developed a novel assay that integrates data from four fusion callers to identify disease-related gene fusions in pediatric tumors with high accuracy and efficiency. The new bioinformatics platform detected fusions, prioritized them, and custom curated downstream processes for consensus fusion calling.

SourceElsevier·JournalJournal of Molecular Diagnostics·TypeExperimental study·DateFeb 13, 2024

RNA sequencing analysis may hold the key to more accurate diagnosis and targeted treatment of pediatric B-acute lymphoblastic leukemia

A pilot study proposes a promising global genomic assay for diagnosing molecular subtypes in pediatric B-ALL, leading to more accurate diagnosis and targeted treatment options. RNA sequencing analysis accurately identified subtypes in all known cases and determined genetic subtype in 79% of previously unknown cases.

SourceElsevier·JournalJournal of Molecular Diagnostics·TypeExperimental study·DateJan 29, 2024

Association for Molecular Pathology publishes best practice guidance for designing and utilizing slice testing approach for diagnostics

The Association for Molecular Pathology published a report outlining considerations for a slice testing strategy, including gene selection and quality. This approach combines the advantages of high-quality gene panels with flexibility and broad scope of exome sequencing.

SourceAssociation for Molecular Pathology·JournalJournal of Molecular Diagnostics·DateDec 20, 2023

Do genes that code athletic heart enlargement carry a risk of future heart problems?

A new study found that one in six elite athletes have reduced heart function and an enrichment of genes associated with heart muscle disease. The research highlights the need for closer monitoring of these athletes' heart health, as their genetic makeup may be 'stressed' by exercise to cause profound heart changes.

SourceVictor Chang Cardiac Research Institute·JournalCirculation·TypeObservational study·DateDec 18, 2023

Genetic testing could greatly benefit patients with depression, save health system millions

A new study suggests that genetic testing for depression could lead to significant cost savings and improved patient outcomes. The test, known as pharmacogenomic testing, can help match patients with medications that are more likely to be effective and cause fewer side effects.

SourceUniversity of British Columbia·JournalCanadian Medical Association Journal·TypeComputational simulation/modeling·DateNov 14, 2023

Trust is the most important factor for British South Asians when taking part in genetic research to tailor medications

A study by Queen Mary University of London reveals that trust is the key factor in British South Asians' participation in genetic testing. Participants emphasize the importance of General Practitioners (GPs) as trustworthy professionals and personalized prescribing with genetic information to enhance trust and medication adherence.

SourceQueen Mary University of London·JournalThe Pharmacogenomics Journal·TypeObservational study·DateOct 31, 2023

Capturing immunotherapy response in a blood drop

A phase 2 clinical trial found that serial blood tests can identify patients who benefit from additional immunotherapies, suggesting a potential early marker of treatment response. The study also showed that ctDNA analyses correlated with tumor size and survival, making it a promising strategy for guiding therapy.

SourceJohns Hopkins Medicine·JournalNature Medicine·DateOct 9, 2023

New insights into the prognostic power of gene expression signatures in breast cancer

The study analyzed 10,000 gene expression signatures to assess their prognostic ability, finding that they lead to accurate patient prognosis in no more than 80% of cases. The researchers emphasize the need for a comprehensive approach incorporating molecular, clinical, histological, and other factors to ensure an accurate prognosis.

SourceUniversität Leipzig·JournalScientific Reports·TypeData/statistical analysis·DateOct 5, 2023